奕拓医药

ETOP Bio is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on pioneering drug discovery through the modulation of protein liquid-liquid phase separation (LLPS). The company utilizes its proprietary platform to develop small molecule therapeutics for challenging targets in oncology and neurodegenerative diseases. Their lead candidate, ET0038, is a highly selective SHP2 inhibitor currently undergoing Phase 1 clinical trials for the treatment of advanced solid tumors. By targeting the physical properties of protein condensates, ETOP Bio aims to unlock therapeutic potential for previously undruggable proteins. The company is backed by prominent life science investors including Qiming Venture Partners and Lilly Asia Ventures.